Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top ...

By Bhanvi Satija and Marleen Kaesebier LONDON, April 28 (Reuters) - Novartis posted first-quarter core operating profit and ...

Novartis has started to show the effects of its patent cliff more strongly, with sales and profits falling in the first ...

Novartis Q1 2026 earnings missed as generic competition hit Entresto sales; Kisqali and Pluvicto growth offsets.

Generic competition for Promacta, a blood disorder drug, and Tasigna, a leukemia treatment, is adding pressure on ​Novartis ...

Novartis reported Q1 earnings below expectations as generics for its top-selling drug Entresto weighed on sales and profits.

(Reuters) -Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to ...

The launch of a generic version of Novartis's (NYSE:NVS) blockbuster cardiac drug Entresto has reportedly been temporarily blocked by a federal appeals court as it considers the drugmaker's request ...

Novartis was unsuccessful in convincing a federal court to block MSN Pharmaceuticals from introducing its own version of Novartis' heart-failure drug Entresto, according to a court decision issued on ...

After more than six years of high-stakes litigation in multiple courts and regulatory fights at the Food and Drug Administration (FDA), generic versions of Novartis Pharmaceuticals Corp.

WASHINGTON, Jan 16 - Novartis (NOVN.S), opens new tab won an order from a U.S. appeals court in Washington on Thursday temporarily blocking drugmaker MSN Pharmaceuticals from launching a generic ...

By Bhanvi Satija and Marleen Kaesebier LONDON, April 28 (Reuters) - Novartis posted first-quarter core operating profit and ...